GLP-1 Market
LLY $1409.38 ▼ -0.1% NVO $40.19 ▼ -0.6% PFE $30.00 ▼ -2.2% VKTX $26.09 ▼ -2.8% KLRA $12.58 ▲ +3.5% GPCR $20.35 ▼ -0.6% RHHBY $59.18 ▼ -2.5%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Belantamab mafodotin

Company
GlaxoSmithKline
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
16 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

16 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Nov 4, 2026

Find a Clinical Trial Near Me

See recruiting studies for Belantamab mafodotin and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT02343042

    Selinexor and Backbone Treatments of Multiple Myeloma Patients

    Not yet reported, Not yet reported Karyopharm Therapeutics Inc 300 participants Est. completion 2027-04 25 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT04643002

    Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

    Not yet reported, Not yet reported Sanofi 258 participants Est. completion 2028-04-20 25 sites Stand-alone
    Other conditions: Plasma Cell Myeloma Refractory
    View official trial listing →
  • Recruiting NCT NCT04822337

    Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

    Not yet reported, Not yet reported Wake Forest University Health Sciences 70 participants Est. completion 2032-11 2 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT05055063

    A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma

    Not yet reported M.D. Anderson Cancer Center 30 participants Est. completion 2027-02-02 1 site Stand-alone
    Other conditions: Myeloma
    View official trial listing →
  • Recruiting NCT NCT05091372

    Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

    Not yet reported M.D. Anderson Cancer Center 94 participants Est. completion 2027-12-31 1 site Stand-alone
    Other conditions: Myeloma Multiple
    View official trial listing →
  • Recruiting NCT NCT05145816

    Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

    Not yet reported, Not yet reported University of Texas Southwestern Medical Center 37 participants Est. completion 2027-09-01 3 sites Stand-alone
    Other conditions: AL Amyloidosis, Amyloidosis
    View official trial listing →
  • Recruiting NCT NCT05208307

    Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma

    Not yet reported Emory University 34 participants Est. completion 2028-10-21 1 site Stand-alone
    Other conditions: Plasma Cell Myeloma
    View official trial listing →
  • Recruiting NCT NCT05714839

    A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

    Not yet reported, Not yet reported GlaxoSmithKline 123 participants Est. completion 2028-08-03 44 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT05789303

    Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma

    Not yet reported University of Chicago 83 participants Est. completion 2028-07-01 2 sites Stand-alone
    Other conditions: Multiple Myeloma, Relapse Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT05847569

    Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma

    Not yet reported Mayo Clinic 62 participants Est. completion 2034-06-29 1 site Stand-alone
    Other conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT05853965

    Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma

    Not yet reported, Not yet reported Universitätsklinikum Hamburg-Eppendorf 45 participants Est. completion 2028-12 5 sites Stand-alone
    Other conditions: Multiple Myeloma, Multiple Myeloma in Relapse
    View official trial listing →
  • Recruiting NCT NCT05922501

    Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma

    Not yet reported Massachusetts General Hospital 50 participants Est. completion 2030-12-31 2 sites Stand-alone
    Other conditions: Relapsed Cancer, Refractory Multiple Myeloma, Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06679101

    A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

    Not yet reported GlaxoSmithKline 520 participants Est. completion 2031-04-28 181 sites Stand-alone
    Other conditions: Multiple Myeloma, Newly Diagnosed Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT07224672

    A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis

    Not yet reported GlaxoSmithKline 60 participants Est. completion 2033-01-12 16 sites Stand-alone
    Other conditions: Amyloidosis
    View official trial listing →
  • Recruiting NCT NCT07227311

    A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

    Not yet reported GlaxoSmithKline 200 participants Est. completion 2030-08-30 59 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT07285239

    Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

    Not yet reported PrECOG, LLC. 500 participants Est. completion 2034-06 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02064387

    Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916

    Not yet reported GlaxoSmithKline 79 participants Est. completion 2019-08-01 9 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03525678

    A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody

    Not yet reported GlaxoSmithKline 221 participants Est. completion 2024-09-12 59 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03544281

    To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

    Not yet reported, Not yet reported GlaxoSmithKline 153 participants Est. completion 2024-02-28 26 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT03715478

    Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex

    Not yet reported, Not yet reported Canadian Myeloma Research Group 120 participants Est. completion 2027-12-31 9 sites
    Other conditions: Relapsed and/or Refractory Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03732703

    Myeloma-Developing Regimens Using Genomics (MyDRUG)

    Not yet reported, Not yet reported Multiple Myeloma Research Consortium 103 participants Est. completion 2024-12-31 16 sites Stand-alone
    Other conditions: Relapsed Refractory Multiple Myeloma
    View official trial listing →
  • Available NCT NCT03763370

    Managed Access Program for Combination Treatment With Belantamab Mafodotin in Multiple Myeloma

    GlaxoSmithKline
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03828292

    An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments

    Not yet reported GlaxoSmithKline 15 participants Est. completion 2024-09-05 4 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03848845

    Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)

    Not yet reported, Not yet reported GlaxoSmithKline 41 participants Est. completion 2023-06-14 12 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04091126

    Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

    Not yet reported GlaxoSmithKline 118 participants Est. completion 2026-12-31 30 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04126200

    Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

    Not yet reported, Not yet reported GlaxoSmithKline 208 participants Est. completion 2027-03-11 38 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04162210

    Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

    Not yet reported GlaxoSmithKline 325 participants Est. completion 2027-03-11 136 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT04177823

    A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

    Not yet reported GlaxoSmithKline 6 participants Est. completion 2021-12-30 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04246047

    Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

    Not yet reported GlaxoSmithKline 494 participants Est. completion 2028-06-30 69 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT04398680

    A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function

    Not yet reported GlaxoSmithKline Est. completion 2025-11-04 18 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04398745

    A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function

    Not yet reported GlaxoSmithKline 36 participants Est. completion 2027-03-11 4 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04484623

    Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

    Not yet reported GlaxoSmithKline 302 participants Est. completion 2029-06-25 122 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT04549363

    Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin

    Not yet reported GlaxoSmithKline 16 participants Est. completion 2022-11-21 6 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT04617925

    A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis

    Not yet reported Stichting European Myeloma Network 35 participants Est. completion 2025-07-17 6 sites Stand-alone
    Other conditions: AL Amyloidosis
    View official trial listing →
  • Terminated NCT NCT04676360

    Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma

    Not yet reported Jacob Soumerai, MD 10 participants Est. completion 2024-11-26 3 sites Stand-alone
    Other conditions: Relapsed Plasmablastic Lymphoma, Refractory Plasmablastic Lymphoma, Anaplastic Lymphoma Kinase Positive Large B-Cell Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT04680468

    Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma

    Not yet reported University of Pennsylvania 41 participants Est. completion 2028-11-01 1 site Stand-alone
    Other conditions: Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04802356

    Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

    Not yet reported PETHEMA Foundation 50 participants Est. completion 2026-06 12 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04808037

    Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

    Not yet reported, Not yet reported Hellenic Society of Hematology 66 participants Est. completion 2028-11-08 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04876248

    Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant

    Not yet reported Roswell Park Cancer Institute 4 participants Est. completion 2027-07-29 1 site Stand-alone
    Other conditions: Plasma Cell Myeloma
    View official trial listing →
  • Terminated NCT NCT04892264

    Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma

    Not yet reported Mayo Clinic 5 participants Est. completion 2024-03-18 1 site Stand-alone
    Other conditions: Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
    View official trial listing →
  • Terminated NCT NCT04896658

    Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

    Not yet reported, Not yet reported University of Maryland, Baltimore 10 participants Est. completion 2024-12-01 1 site Stand-alone
    Other conditions: Relapsed/Refractory Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT05002816

    Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma

    Not yet reported, Not yet reported Yale University 24 participants Est. completion 2026-12 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT05060627

    Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide

    Not yet reported, Not yet reported PETHEMA Foundation 60 participants Est. completion 2028-05-30 15 sites Stand-alone
    Other conditions: Relapsed Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT05064358

    Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma

    Not yet reported GlaxoSmithKline 177 participants Est. completion 2026-02-10 77 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT05065047

    Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma

    Not yet reported M.D. Anderson Cancer Center 6 participants Est. completion 2025-11-06 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT05117008

    Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma

    Not yet reported Medical College of Wisconsin 1 participants Est. completion 2024-01-15 1 site Stand-alone
    Other conditions: Refractory Multiple Myeloma, Relapse Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT05280275

    A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible

    Not yet reported, Not yet reported Hellenic Society of Hematology 36 participants Est. completion 2026-03-15 2 sites Stand-alone
    Other conditions: Multiple Myeloma, Neoplasms, Neoplasms, Plasma Cell, Gammopathy, Monoclonal, Paraproteinemias, Blood Protein Disorders, Haematologic Disease, Corneal Disease
    View official trial listing →
  • Status unknown NCT NCT05297240

    Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain.

    PETHEMA Foundation 170 participants Est. completion 2022-12 62 sites
    Other conditions: RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
    View official trial listing →
  • Completed NCT NCT05349383

    Evaluation of Reporting of Antibody-Drug Conjugate Associated Sepsis-related Toxicities

    Central South University 24618 participants Est. completion 2022-06-01 1 site
    Other conditions: Sepsis (SMQ), Opportunistic Infections, Agranulocytosis
    View official trial listing →
  • Completed NCT NCT05393024

    Patient With MMRR Treated With Belantamab Mafotidine on Monotherapy

    Fondazione EMN Italy Onlus 78 participants Est. completion 2024-08-12 10 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT05461209

    A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC Est. completion 2024-10-31 2 sites
    Other conditions: Relapsed/ Refractory Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT05493618

    Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.

    Not yet reported, Not yet reported Hackensack Meridian Health Est. completion 2025-11 3 sites Stand-alone
    Other conditions: Multiple Myeloma, Refractory
    View official trial listing →
  • Active, not recruiting NCT NCT05556798

    A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment

    Not yet reported Memorial Sloan Kettering Cancer Center 9 participants Est. completion 2027-10 7 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT05573802

    A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma

    Not yet reported, Not yet reported Hellenic Society of Hematology 36 participants Est. completion 2026-10-31 2 sites Stand-alone
    Other conditions: Multiple Myeloma, Neoplasms, Neoplasm, Plasma Cell, Gammopathy, Monoclonal, Paraproteinemias, Blood Protein Disorders, Haematologic Disease, Corneal Disease
    View official trial listing →
  • Status unknown NCT NCT05581875

    A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory

    Not yet reported, Not yet reported Hellenic Society of Hematology 48 participants Est. completion 2026-10-31 Stand-alone
    Other conditions: Multiple Myeloma, Multiple Myeloma in Relapse, Neoplasms, Gammopathy, Monoclonal, Paraproteinemias, Blood Protein Disorders, Haematologic Disease, Corneal Disease, Neoplasms, Plasma Cell
    View official trial listing →
  • Terminated NCT NCT05833737

    Corneal Findings in Patients Treated With Belantamab Mafodotin

    Medical University of Vienna 12 participants Est. completion 2025-01-01 1 site
    Other conditions: Multiple Myeloma, Corneal Diseases, Corneal Cyst
    View official trial listing →
  • Withdrawn NCT NCT05874193

    A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma

    Not yet reported Cristiana Costa Chase, DO Est. completion 2028-11 5 sites Stand-alone
    Other conditions: Relapsed/Refractory Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT05887206

    Corneal Toxicity in Patients Treated by Belantamab Mafodotin

    Centre Hospitalier Universitaire de Saint Etienne 43 participants Est. completion 2023-05-02 10 sites
    Other conditions: Myeloma Multiple
    View official trial listing →
  • Completed NCT NCT05986682

    Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma

    Duke University 30 participants Est. completion 2023-11-07 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT06160609

    Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM

    Not yet reported, Not yet reported GlaxoSmithKline 9 participants Est. completion 2023-01-09 3 sites Stand-alone
    Other conditions: Relapsed/Refractory Multiple Myeloma
    View official trial listing →
  • Suspended NCT NCT06232044

    Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma

    Not yet reported, Not yet reported Alliance for Clinical Trials in Oncology 88 participants Est. completion 2030-08-01 43 sites Stand-alone
    Other conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT06413511

    A Study to Investigate the Safety and Pharmacological Effect of a Single Intravenous Infusion of Belantamab in Male and Female Participants Aged 18 to 75 With Autoimmune Disease

    Not yet reported GlaxoSmithKline Est. completion 2025-07-08
    Other conditions: Autoimmune Diseases
    View official trial listing →
  • Terminated NCT NCT06655818

    Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM

    Not yet reported, Not yet reported GlaxoSmithKline 4 participants Est. completion 2024-02-14 3 sites Stand-alone
    Other conditions: Relapsed/Refractory Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT06868654

    China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

    Not yet reported GlaxoSmithKline 72 participants Est. completion 2028-06-30 11 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT06868667

    Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

    Not yet reported GlaxoSmithKline 24 participants Est. completion 2028-06-30 16 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT06956170

    All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

    Not yet reported GlaxoSmithKline 21 participants Est. completion 2029-06-25 13 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Not yet recruiting NCT NCT07019545

    A PHASE II TRIAL AIMING TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA PREVIOUSLY TREATED WITH A THROMBOPOIETIN RECEPTOR AGONIST AND/OR RITUXIMAB AFTER CORTICOSTEROID FIRST-LINE THERAPY

    Not yet reported Hellenic Society of Hematology 14 participants Est. completion 2027-06-20 1 site
    Other conditions: Primary Immune Thrombocytopenia (ITP)
    View official trial listing →
  • Active, not recruiting NCT NCT07084896

    Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM

    Not yet reported, Not yet reported GlaxoSmithKline 106 participants Est. completion 2027-03-11 29 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT07150091

    Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM

    Not yet reported, Not yet reported GlaxoSmithKline 20 participants Est. completion 2027-03-11 12 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT07150104

    Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM

    Not yet reported, Not yet reported GlaxoSmithKline 14 participants Est. completion 2027-03-11 10 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT07217119

    Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM

    Not yet reported, Not yet reported GlaxoSmithKline 25 participants Est. completion 2027-03-11 11 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT07217184

    Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM

    Not yet reported, Not yet reported GlaxoSmithKline 30 participants Est. completion 2027-03-11 19 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Not yet recruiting NCT NCT07609706

    A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment

    Not yet reported GlaxoSmithKline 20 participants Est. completion 2031-08-22 Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Not yet recruiting NCT NCT07612787

    A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma

    Not yet reported, Not yet reported Centre Hospitalier Universitaire de Saint Etienne 44 participants Est. completion 2031-01-01 30 sites
    Other conditions: Myeloma Multiple
    View official trial listing →
  • Not yet recruiting NCT NCT07614360

    Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma

    Not yet reported GlaxoSmithKline 150 participants Est. completion 2031-02-11 Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Not yet recruiting NCT NCT07637526

    Study to Evaluate Efficacy and Safety of Belantamab-based Combinations for Relapsed Multiple Myeloma

    PETHEMA Foundation 100 participants Est. completion 2027-12-31
    Other conditions: Relapse Multiple Myeloma
    View official trial listing →
  • Not yet recruiting NCT NCT07720843

    TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM)

    Not yet reported Montefiore Medical Center 50 participants Est. completion 2032-03 Stand-alone
    Other conditions: Relapse Multiple Myeloma, Refractory Multiple Myeloma
    View official trial listing →
  • Not yet recruiting NCT NCT07748689

    Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.

    Not yet reported Polish Myeloma Consortium 228 participants Est. completion 2033-03 Stand-alone
    Other conditions: Relapsed / Refractory Multiple Myeloma
    View official trial listing →
  • Not yet recruiting NCT NCT07831122

    Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)

    Not yet reported Canadian Myeloma Research Group 108 participants Est. completion 2033-03 7 sites
    Other conditions: Relapsed Refractory Multiple Myeloma (RRMM)
    View official trial listing →
  • Not yet recruiting NCT NCT07844200

    The Primary Objective of the Trial is to Evaluate the Effect of the Addition of Belantamab Mafodotin to Standard of Care Therapy on the Titres of Serum Anti-dsDNA Antibodies in Patients With Previously Treated SLE.

    Not yet reported Medical Association for the Study of Cancer Biology and Treatment 12 participants Est. completion 2031-12
    Other conditions: SLE - Systemic Lupus Erythematosus
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.